142 results about "Antithrombotic" patented technology

The invention relates to ultra-small prussian blue nano-particles (T-USPB-C) carrying tirofian, a preparation method of the nano-particles and application of the nano-particles in preparation of drugs for reducing MVO and MIRI. According to the preparation method, the T-USPB-C is prepared by three steps. The T-USPB-C provided by the invention can carry tirofiban, and has catalase and superoxide dismutase simulated nano-enzyme activity. Moreover, the size of the nano-scale drug is required to reach a nano-scale size, and the drug can be efficiently cleared through kidney excretion, so that the potential long-term toxicity problem is minimized. The ultra-small prussian blue nanoparticle carrying the tirofian has an excellent active oxygen scavenging capability. Microvascular perfusion can be rapidly improved through the antithrombotic effect, then the protection effect is continuously achieved through the anti-oxidation and anti-inflammatory mechanism, and microvascular injury and MIRI are effectively prevented.

The invention belongs to the technical field of biomedical materials, and particularly relates to a poly-4-methyl-1-pentene (PMP) gas-blood exchange membrane for an extracorporeal membrane oxygenation (ECMO) system, which realizes a long-acting antithrombotic function through a bionic interface construction technology. The invention aims to provide a bionic antithrombotic PMP gas-blood exchange membrane based on zwitter-ion gradient grafting, and through material and process innovation, the following problems existing in a traditional ECMO gas-blood exchange membrane: an antithrombotic coating is easy to fall off, and the long-term effect is insufficient; the risk of blood injury caused by dependence on heparin or anticoagulants; and the surface modification process destroys the membrane pore structure and air permeability.

The invention relates to the technical field of traditional Chinese medicine health-care products, and particularly discloses an earthworm protein peptide composition for improving vascular embolism and a preparation method thereof.The earthworm protein peptide composition is prepared from, by weight, 28-34 parts of earthworm protein peptide, 20-26 parts of active pharmaceutical ingredients, 1-5 parts of ginkgo biloba extract, 12-15 parts of corn oligopeptide powder and 4-8 parts of auxiliary materials; lumbricus protein peptide, active pharmaceutical ingredients, ginkgo biloba extract and corn oligopeptide powder are used as raw materials, a solubilizing component is added in the preparation process, the solubilizing component is prepared by mixing functional extract, nattokinase and tween-80 according to a certain proportion, the functional extract is prepared by coating grape seed extract with hydroxypropyl-beta-cyclodextrin, and the solubilizing component is prepared by mixing the functional extract, the nattokinase and the tween-80 according to a certain proportion. Through the synergistic effect of the components, the antithrombotic effect of the earthworm protein peptide composition is synergistically enhanced.

The invention belongs to the technical field of microorganisms and biological medicines, and particularly relates to a postbiotic preparation for improving vascular elasticity and relieving hypertension and thrombus as well as a preparation method and application of the postbiotic preparation. Specifically, a strain of lactobacillus rhamnosus is obtained through screening, a postbiotic preparation is successfully developed based on the strain, and tests prove that the lactobacillus rhamnosus has the effects of reducing inflammatory response of vascular endothelium and reducing oxidative stress level so as to promote repair and regeneration of vascular endothelial cells, improve vascular elasticity and quickly improve hypertension; the anti-thrombus effect can be realized. Meanwhile, by optimizing the condition parameters of the preparation process of the metabolite preparation and combining anaerobic fermentation and aerobic fermentation on the lactobacillus rhamnosus, the advantage that metabolites are comprehensive and rich is achieved, and the metabolite preparation has good practical application value.

In one aspect, the invention provides compositions and methods for preventing, reducing, and / or treating a disease, disorder or condition associated with fibrin-induced activation of the complement system and the associated activation of the coagulation and / or contact systems comprising administering a therapeutic amount of a MASP-2 inhibitory antibody to a subject in need thereof. In some embodiments, the methods of the invention provide anticoagulation and / or antithrombosis and / or antithrombogenesis without affecting hemostasis. In one embodiment of this aspect of the invention, the compositions and methods are useful for treating a subject is suffering from, or at risk of developing, a disease, disorder or condition associated with complement-related inflammation, excessive coagulation or contact system activation initiated by fibrin or activated platelets.

The invention relates to a medical device for treating aneurysms, in particular a stent, including a compressible and expandable grid structure made up of grid elements. The grid structure has at least one closed cell ring which includes at most 12, in particular at most 10, in particular at most 8, in particular at most 6 cells directly adjacent to one another in a circumferential direction of the grid structure. The grid structure is provided at least in certain portions with a covering made of an electrospun fabric which has pores of irregular sizes. The covering includes over a surface area of 100 000 μm2 at least 10 pores which have a size of at least 15 μm2. The covering has a biocompatible, in particular antithrombogenic and / or endothelialization-promoting coating.

A series of sofalcone derivatives are provided.SOLUTION: A series of sofalcone derivatives provided by the present invention are, for example, compounds having a structure of formula (I), and have platelet aggregation inhibitory and antithrombotic effects. The sofalcone derivatives of the present invention are TxA2 receptor antagonists, have an inhibitory effect on platelet agglutination, and do not easily affect the hemostatic function. The present invention also provides a method for preparing the sofalcone derivative, and a method for using the sofalcone derivative for preventing or treating thrombotic diseases, or for inhibiting platelet aggregation.SELECTED DRAWING: None

Refreshing stylets, catheter systems, and methods thereof. The refreshing stylet can be configured to fit within a lumen of a catheter such as hemodialysis catheter. The refreshing stylet can include an elongated hollow body having a proximal portion coupled to a needleless connector, a distal portion ending in a distal tip, an interior surface, an exterior surface, and a side hole. The exterior surface can be coated with a sustained-release formulation including one or more anti-thrombotic agents. The sustained-release formulation can be configured to contact a luminal surface of the catheter and prevent thrombus formation thereon. The side hole can be configured to provide a locking solution to the lumen of the catheter for locking the catheter between uses.

This invention relates to the fields of molecular biology and biomedicine, disclosing plasma-active peptides with antithrombotic effects and their uses. The invention obtains various active peptides from plasma through screening and solid-phase synthesis, and confirms their biological activity through in vitro platelet aggregation experiments and in vivo arterial thrombosis model experiments. Results show that peptides 1957, 1960, and 1961 significantly inhibit collagen-induced platelet aggregation, exhibiting good antiplatelet activity; animal experiments show that peptides 1955, 1957, 1960, and 1961 significantly inhibit arterial thrombosis. These active peptides are derived from endogenous plasma components, belonging to natural antithrombotic substances, possessing good physiological compatibility and safety advantages, and reducing the risk of immunogenicity and adverse reactions. These peptides can exert antithrombotic effects without relying on traditional antiplatelet drugs, providing a new source of active molecules and treatment options for the prevention and treatment of thrombotic diseases.

The application discloses a nitrogen acetylated carbazole alkaloid, and the structure is selected from one of the following structures: The application discloses a nitrogen acetylated carbazole alkaloid produced by fermentation of streptomyces J1074, and provides a biosynthetic preparation method, which is more green and environmental protection, and cost reduction compared with a chemical synthesis method; the compound ATC-A provided by the application shows significant antithrombotic activity in a thrombotic zebrafish model, which may be related to down-regulation of gene expression related to platelet activation and blood coagulation cascade, and has important development prospect and clinical application value.

Provided are a novel antithrombotic antibody targeting a blood coagulation factor FIXa-FVIIIa binding site and an application thereof.SOLUTION: The present invention provides a novel antithrombotic antibody, which targets FIXa and has unique properties, specifically targets the binding site of blood coagulation factors FIXa and FVIIIa, reduces the formation of FVIIIa-FIXa complex, blocks the conversion of FX to FXa, and exerts an antithrombotic effect. The antibody of the present invention has an appropriate antithrombotic performance and a large effective therapeutic concentration window, but does not increase the bleeding risk, which can achieve the need for moderate antithrombosis and effectively avoid the bleeding problem caused by excessive action in clinical applications. The present invention also discloses methods of screening for drugs that target the FIXa-FVIIIa binding site.SELECTED DRAWING: Figure 1A

The invention relates to a preparation method of an artificial blood vessel, the artificial blood vessel is composed of a porous support layer, a biodegradation layer and an antithrombotic layer, and the method comprises the following steps: soaking an expanded polytetrafluoroethylene substrate with silver nitrate doped polyvinyl pyrrolidone-poly-N-isopropylacrylamide to obtain the porous support layer; and then assembling a biodegradable material and an antithrombotic material as a biodegradable layer and an antithrombotic layer. The invention also relates to the artificial blood vessel prepared by the method.

The invention belongs to the technical field of medicines, and discloses application of pantethine in preparation of medicines for preventing and / or treating thrombotic diseases or medicines for inhibiting platelet activation or regulating vascular endothelial cell functions. In-vivo and in-vitro experiments prove that pantethine can remarkably relieve thrombus load in a mouse thrombus model, down-regulate expression of vWF (von Willebrand Factor), up-regulate expression of TFPI (Tissue Factor Path Inhibitor) and TH BD (Thromboregulatory Protein), and antagonize platelet adhesion, aggregation and activation induced by a platelet activator. The action mechanism is closely related to inhibition of reactive oxygen species (ROS) generation and NF-kappa B signal channel activation, and improvement of endothelial cell functions. It can be known from the invention that pantethine plays an antithrombotic role from multiple aspects, and is suitable for preparation of antithrombotic drugs for prevention or treatment. The invention provides a new drug choice for prevention and treatment of thrombotic diseases.

The invention relates to the technical field of medical instruments, in particular to an internal and external fiber coated intravascular stent as well as a preparation method and application thereof. An inner fiber covering film and an outer fiber covering film with certain functions are respectively prepared by utilizing a coaxial electrostatic spinning technology, and the fiber covering film with a core-shell structure is prepared. The inner-layer fiber covering film takes a degradable polymer as a shell layer preparation raw material, so that the shell layer can be degraded within a certain time, thrombus and inflammation resistance is realized, and endothelialization is promoted; the anti-thrombus substance loaded on the shell layer is used for resisting acute thrombus, and can be used as a protective layer to ensure the activity of the substance for promoting vascular endothelial growth in the core layer, and the load can realize a slow release function, so that the loss of expected functions due to quick release of the load is avoided. The outer fiber membrane takes a degradable polymer as a shell layer preparation raw material, so that the shell layer can be degraded within a certain time, and tissue integration and infection resistance are promoted; antibacterial substances are loaded on the core layer and are slowly released under the wrapping of the shell layer.

The invention discloses a 5 / 8 / 5 chitosan clostridium diterpenoid compound, a biosynthetic gene cluster and application of the biosynthetic gene cluster, and relates to the technical field of biological medicines. A 5 / 8 / 5 chitin type diterpenoid biosynthetic gene cluster Thm in trichoderma harzianum is identified through a genome mining system, chitin diterpenoid compounds with diversified structures are obtained by means of heterologous expression, the obtained compounds are subjected to anti-thrombotic activity comprehensive evaluation, and the result shows that the compounds 6 and 31 can obviously inhibit vascular thrombosis, the compound 6 has a remarkable inhibition effect on collagen-induced platelet aggregation, and the compound 31 has a better inhibition capability on thrombin-induced platelet activation. The compounds 6 and 31 show powerful antithrombotic effects in artery, vein and pulmonary artery thrombosis models, so that powerful technical support is provided for development of antithrombotic drugs.

The invention discloses a natural functional component for preventing and improving cardiovascular diseases of pets. The natural functional component comprises an earthworm protein extract and a leech extract, the earthworm protein extract accounts for 20wt%-40wt% of the natural functional components; the ratio of the leech extract in the natural functional components is 10wt%-30wt%; the invention also comprises a feed containing the natural functional components for preventing and improving cardiovascular diseases of pets. The traditional Chinese medicine composition has the effects of resisting blood coagulation, thrombus, inflammation and oxidative stress, can prevent thrombosis, relieve inflammatory response, reduce free radical damage and protect the health of heart and cerebral vessels, and plays a role in preventing and improving cardiovascular diseases of pets; the pet feed additive can be added into feed to protect pet health.

Provided herein is a device including a housing having a proximal end, a distal end, and a sidewall therebetween defining an interior, a fluid conduit displaceably received within the housing interior and having a proximal end and a distal end, the fluid conduit having a first conduit portion at the proximal end of the fluid conduit and a second conduit portion at the distal end of the fluid conduit, wherein the fluid conduit is configured to be advanced from a first, proximal position in which the second conduit portion does not extend beyond a distal end of a catheter of the intravenous catheter assembly to a second, distal position in which the second conduit portion extends beyond a distal end of a catheter of the intravenous catheter assembly, wherein at least a portion of the fluid conduit is configured to be antithrombogenic.

The application discloses a polypeptide FXIa inhibitor FXIapepin with high inhibition and high specificity. Since FXIa can be used as a low hemorrhage risk anti-thrombus treatment target, the polypeptide inhibitor can be used for preparing a drug for developing a low hemorrhage risk treatment or prevention of a thrombotic disease, and has a wide application prospect.

The invention provides an isoquinoline derivative with a novel structure, a pharmaceutically acceptable salt thereof, a preparation method of the isoquinoline derivative, a pharmaceutical composition containing the isoquinoline derivative and pharmaceutical application of the isoquinoline derivative, and belongs to the technical field of medicines. In-vitro experiments show that the isoquinoline derivative has significant inhibitory activity on arachidonic acid-induced platelet aggregation, and the antiplatelet activity of part of compounds is superior to that of aspirin. In a rat carotid artery thrombosis model induced by FeCl3, the isoquinoline derivative remarkably prolongs thrombosis time and reduces thrombus weight, and the in-vivo antithrombotic curative effect of the isoquinoline derivative is equivalent to that of aspirin and ticagrelor. A mouse tail bleeding model shows that the side effects of bleeding amount and bleeding time of the isoquinoline derivative are obviously lower than those of aspirin and ticagrelor. Therefore, the series of isoquinoline derivatives have the advantages of efficient antithrombotic effect and low bleeding risk, and have good application prospects in preparation of drugs for preventing and treating thrombotic diseases. In addition, the preparation method provided by the invention has the advantages of easily available raw materials, simple steps and strong operability, and the obtained target product has high quality and good efficiency.

The invention belongs to the technical field of biological materials, and particularly discloses a construction method of an anti-protein adsorption and antithrombotic graphene oxide coating, which comprises the following steps: step 1, carboxylating graphene oxide to obtain carboxylated graphene oxide nanoparticles; step 2, grafting heparin to the carboxylated graphene oxide nanoparticles; step 3, the graphene oxide-heparin nanoparticles are combined with polyethylene glycol, and graphene oxide-heparin-polyethylene glycol nanoparticles are obtained; and step 4, combining the graphene oxide-heparin-polyethylene glycol nanoparticles with a biological material. The preparation method has the advantages that the biocompatibility of the medical cardiovascular biological material is improved, the protein adsorption resistance and the thrombus resistance of the medical cardiovascular biological material are improved, and the in-vivo stability of the biological material is improved.

The invention discloses application of a compound in preparation of a medicine for treating or relieving ADPGK activation related concurrent diseases in chronic kidney diseases. The compound is found to be capable of effectively inhibiting the activity of ADPGK through computer virtual screening in combination with an in-vitro platelet activation experiment. In CKD patient and mouse models, the Z809269780 significantly reduces the glycolysis flux of platelets, lactic acid generation and RHOA lactylation level, thereby inhibiting the excessive activation and high reactivity of the platelets, and effectively relieving thrombosis events (such as platelet aggregation, adhesion, blood clot retraction and arterial thrombosis). Animal experiments show that intraperitoneal injection of the Z809269780 (10 mg / kg) has a good antithrombotic effect, and the Z809269780 does not show obvious toxicity under the dosage of 20 mg / kg. The invention provides a safe and effective novel targeted treatment strategy for preventing thrombotic complications of CKD patients.

A catheter assembly may include a catheter adapter, which may include a distal end, a proximal end, and a lumen extending through the distal end of the catheter adapter and the proximal end of the catheter adapter. The catheter assembly may include a catheter extending distally from the distal end of the catheter adapter. The catheter assembly may include an introducer needle extending through the catheter. An anti-thrombogenic material may be extruded through a die and / or molded to form one or more portions of the catheter assembly. Additionally or alternatively, inner surfaces and / or outer surfaces of one or more portions of the catheter assembly may be coated with an anti-thrombogenic coating that includes the anti-thrombogenic material.

The present application relates to the field of food, health care products and medicine, and specifically relates to a purslane oral composition for regulating blood lipid and resisting atherosclerosis, and a preparation method and application thereof. The present application takes purslane extract, galangal extract and borneol as core components, and realizes the synergistic effects of lipid regulation, anti-inflammation, reduction of plaque area, stabilization of vulnerable plaque, mild anti-thrombus and myocardial protection through scientific proportioning. The bioavailability is significantly improved by combining the tongue sublingual absorption of borneol and the mucosal penetration of galangal volatile oil. The composition has comprehensive targets, definite effects and good safety, and can be made into oral dosage forms such as buccal tablets, dripping pills and oral disintegrating tablets, and is suitable for daily oral care of cardiovascular sub-healthy people.

The application discloses a kind of nano-medicines with NO catalytic performance and its application in infective endocarditis treatment.The application dissolves molybdate and hydrogen phosphate in water respectively, then the two solutions are stirred and mixed to form Keggin type heteropoly acid of oxidized molybdenum base by self-assembly, i.e., the nano-medicines with NO catalytic performance (OX).The nano-medicines prepared by the application have GSNO catalytic properties and multiple antibacterial properties, and also have antithrombotic and vascular regulation functions, can efficiently catalyze endogenous GSNO to generate NO, through the synergistic effect of "oxidation antibacterial-NO regulation" dual functions, to realize efficient treatment of infective endocarditis.

The application specifically discloses a kind of nanovaccine for thrombosis prevention and its preparation method and application, it is related to thrombotic disease, especially related to the nanovaccine for treating thrombotic disease.The nanovaccine provided by the application has good immunogenicity without macromolecular heterologous protein carrier such as KLH;The process simplicity and repeatability are improved by reducing complex chemical coupling and purification steps;The dependence on traditional high-stimulating immune adjuvant is reduced, and the biological safety is improved;The stability of antigen in gastrointestinal environment is significantly improved;Active targeting delivery of M cells and dendritic cells is realized;Dendritic cell maturation and antigen presentation are promoted, and mucosal immunity and systemic immunity level are improved;The advantages such as effectively inhibiting thrombosis are realized, and a new type of oral antithrombotic vaccine system with high compliance suitable for long-term thrombosis prevention is constructed.

The present application provides a kind of nereid polypeptide antithrombotic preparation, belong to the technical field of biopharmaceuticals.The present application finds that nereid plasmin polypeptide can inhibit the reaction of thrombin and fibrinogen to generate fibrin, thereby inhibiting the blood clotting reaction through in vitro test.Nereid plasmin polypeptide is determined for in vitro anti-platelet aggregation activity, and the inhibition rate of 640 μg / ml nereid plasmin polypeptide for anti-platelet aggregation is 75.68%, close to the inhibition effect of 1 mg / ml aspirin.The present application finds that nereid plasmin polypeptide group has the pharmacodynamic effect of reducing the weight of thrombus and the ratio of thrombus weight and length through nereid plasmin polypeptide antithrombotic effect test, has good antithrombotic effect, and can be used as nereid polypeptide antithrombotic preparation.

Embodiments herein include multilayer thromboresistant coatings and medical devices including the same. In various embodiments, the thromboresistant coating can include a medical device with an antithrombogenic coating comprising a substrate, a tie layer disposed over the substrate, a hydrophilic layer disposed over the tie layer, and a heparin layer disposed over the hydrophilic layer. The hydrophilic layer comprises a photo-PVP compound and the heparin layer comprises a photo-heparin. The tie layer, the hydrophilic layer, and the heparin layer are less than or equal to 100 nm thick in total. Other embodiments are also included herein.

The invention relates to the technical field of enzyme engineering and bioactive peptide preparation, and discloses a preparation method of horse myocardial peptide with antioxidant and antithrombotic effects, and the preparation method comprises the following steps: S1, pretreating horse heart tissue to obtain horse myocardial pulp; s2, composite enzymatic hydrolysis and guiding agent regulation and control: adding a composite enzyme system and an anti-thrombus guiding agent into the horse myocardial plasma; and S3, affinity chromatography enrichment. According to the method disclosed by the invention, a composite enzymolysis, guide regulation and control and affinity enrichment synergistic process is constructed, so that the technical problems of incomplete tissue crushing, low enzymolysis efficiency, insufficient bioactive peptide yield and easiness in oxidation and inactivation caused by high proportion of IIa type muscle fibers and compact connective tissues of horse myocardium are solved in a targeted manner, and a compound enzyme system with a specific ratio is adopted to adapt to the characteristics of the horse myocardium; the enzymolysis efficiency is greatly improved, a cationic guiding agent is introduced to directionally improve the generation proportion of antithrombotic peptide fragments, efficient enrichment of target peptides is achieved by combining thrombin affinity chromatography, and the antithrombotic function is remarkably enhanced while high antioxidant activity is guaranteed.

The present application relates to the technical field of biology, and discloses a cell preservation solution, a preparation method and preparation thereof, and a cell preservation method. The cell preservation solution contains 1-10 mL compound electrolyte glucose injection, 1-10 mL human blood albumin injection, 1-10 mL compound amino acid injection, 10-20 uM salvianolic acid B, 20-60 uM rhodioside, and 1-10 uM ginkgo biloba bilobal, and the compound electrolyte injection is supplemented. The cell preservation solution can improve the biological activity of cells and prolong the preservation time of cells in multiple ways by adding traditional Chinese medicine extracts as antioxidants, membrane stabilizers and antithrombotics in response to the excess of free radicals in the low-temperature preservation process.